{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:38:04Z","timestamp":1795084684780,"version":"4.10.2"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-023-02551-6","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T17:03:11Z","timestamp":1680022991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["RETRACTED ARTICLE: Loteprednol-Loaded Nanoformulations for Corneal Delivery by Quality-by-Design Concepts: Optimization, Characterization, and Anti-inflammatory Activity"],"prefix":"10.1208","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4691-0432","authenticated-orcid":false,"given":"Burcu","family":"Uner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samet","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cetin","family":"Tas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melike","family":"Uner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yildiz","family":"Ozsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"issue":"2","key":"2551_CR1","first-page":"203","volume":"14","author":"W Ericson-Neilsen","year":"2014","unstructured":"Ericson-Neilsen W, Kaye AD. Steroids: pharmacology, complications, and practice delivery issues. Ochsner J. 2014;14(2):203\u20137.","journal-title":"Ochsner J"},{"key":"2551_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jconrel.2015.01.009","volume":"201","author":"Q Pan","year":"2015","unstructured":"Pan Q, Xu Q, Boylan NJ, Lamb NW, Emmert DG, Yang JC, et al. Corticosteroid-loaded biodegradable nanoparticles for prevention of corneal allograft rejection in rats. J Control Release. 2015;201:32\u201340.","journal-title":"J Control Release"},{"issue":"8","key":"2551_CR3","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1097\/ICO.0000000000001982","volume":"38","author":"EJ Holland","year":"2019","unstructured":"Holland EJ, Fingeret M, Mah FS. Use of topical steroids in conjunctivitis: a review of the evidence. Cornea. 2019;38(8):1062\u20137.","journal-title":"Cornea"},{"issue":"4","key":"2551_CR4","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ophtha.2011.10.016","volume":"119","author":"J Shimazaki","year":"2012","unstructured":"Shimazaki J, Iseda A, Satake Y, Shimazaki-Den S. Efficacy and safety of long-term corticosteroid eye drops after penetrating keratoplasty: a prospective, randomized, clinical trial. Ophthalmology. 2012;119(4):668\u201373.","journal-title":"Ophthalmology"},{"issue":"46","key":"2551_CR5","doi-asserted-by":"publisher","first-page":"27835","DOI":"10.1039\/D0RA04971A","volume":"10","author":"S Gorantla","year":"2020","unstructured":"Gorantla S, Rapalli VK, Waghule T, Singh PP, Dubey SK, Saha RN, et al. Nanocarriers for ocular drug delivery: current status and translational opportunity. RSC Adv. 2020;10(46):27835\u201355.","journal-title":"RSC Adv"},{"issue":"4","key":"2551_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/14656566.2018.1439920","volume":"19","author":"TL Comstock","year":"2018","unstructured":"Comstock TL, Sheppard JD. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. Expert Opin Pharmacother. 2018;19(4):337\u201353.","journal-title":"Expert Opin Pharmacother"},{"key":"2551_CR7","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.2147\/OPTH.S210597","volume":"13","author":"R Fong","year":"2019","unstructured":"Fong R, Cavet ME, DeCory HH, Vittitow JL. Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two phase III clinical studies. Clin Ophthalmol. 2019;13:1427\u201338.","journal-title":"Clin Ophthalmol."},{"key":"2551_CR8","first-page":"751","volume":"5","author":"R Reddy","year":"2011","unstructured":"Reddy R, Kim SJ. Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery. Clin Ophthalmol. 2011;5:751\u20138.","journal-title":"Clin Ophthalmol"},{"key":"2551_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ejpb.2016.10.015","volume":"109","author":"SP Balguri","year":"2016","unstructured":"Balguri SP, Adelli GR, Majumdar S. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. Eur J Pharm Biopharm. 2016;109:224\u201335.","journal-title":"Eur J Pharm Biopharm"},{"key":"2551_CR10","first-page":"457","volume-title":"Properties and therapeutic potential of solid lipid nanoparticles and nanostructured lipid carriers as promising colloidal drug delivery systems","author":"S \u00d6zdemir","year":"2019","unstructured":"\u00d6zdemir S, \u00c7elik B, \u00dcner M. Properties and therapeutic potential of solid lipid nanoparticles and nanostructured lipid carriers as promising colloidal drug delivery systems. Materials for Biomedical Engineering: Elsevier; 2019. p. 457\u2013505."},{"issue":"43","key":"2551_CR11","doi-asserted-by":"publisher","first-page":"6573","DOI":"10.2174\/1381612823666171122110638","volume":"23","author":"M Uner","year":"2017","unstructured":"Uner M, Damgali S, Ozdemir S, Celik B. Therapeutic potential of drug delivery by means of lipid nanoparticles: reality or illusion? Curr Pharm Des. 2017;23(43):6573\u201391.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"2551_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/bjo.85.4.437","volume":"85","author":"LJ M\u00fcller","year":"2001","unstructured":"M\u00fcller LJ, Pels E, Vrensen GF. The specific architecture of the anterior stroma accounts for maintenance of corneal curvature. Br J Ophthalmol. 2001;85(4):437\u201343.","journal-title":"Br J Ophthalmol"},{"issue":"1\u20132","key":"2551_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0378-5173(02)00298-3","volume":"244","author":"B Siekmann","year":"2002","unstructured":"Siekmann B, Bunjes H, Koch MH, Westesen K. Preparation and structural investigations of colloidal dispersions prepared from cubic monoglyceride\u2013water phases. Int J Pharm. 2002;244(1\u20132):33\u201343.","journal-title":"Int J Pharm"},{"issue":"1","key":"2551_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/acph-2015-0009","volume":"65","author":"\u00dc G\u00f6n\u00fcll\u00fc","year":"2015","unstructured":"G\u00f6n\u00fcll\u00fc \u00dc, \u00dcner M, Yener G, Fatma Karaman E, Aydo\u011fmu\u015f Z. Formulation and characterization of solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsion of lornoxicam for transdermal delivery. Acta Pharmaceutica. 2015;65(1):1\u201313.","journal-title":"Acta Pharmaceutica."},{"issue":"3","key":"2551_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/08982100802702046","volume":"19","author":"G Deli","year":"2009","unstructured":"Deli G, Hatziantoniou S, Nikas Y, Demetzos C. Solid lipid nanoparticles and nanoemulsions containing ceramides: preparation and physicochemical characterization. J Liposome Res. 2009;19(3):180\u20138.","journal-title":"J Liposome Res"},{"key":"2551_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jddst.2018.03.011","volume":"45","author":"S \u00d6zdemir","year":"2018","unstructured":"\u00d6zdemir S, \u00c7elik B, Acar ET, Duman G, \u00dcner M. Eplerenone nanoemulsions for treatment of hypertension. Part I: Experimental design for optimization of formulations and physical characterization. J Drug Deliv Sci Technol. 2018;45:357\u201366.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"8","key":"2551_CR17","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s11094-019-02070-4","volume":"53","author":"AS Dhoot","year":"2019","unstructured":"Dhoot AS, Fernandes GJ, Naha A, Rathnanand M, Kumar L. Design of experiments in pharmaceutical development. Pharm Chem J. 2019;53(8):730\u20135.","journal-title":"Pharm Chem J"},{"issue":"8","key":"2551_CR18","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1039\/C5OB01892G","volume":"14","author":"PM Murray","year":"2016","unstructured":"Murray PM, Bellany F, Benhamou L, Bu\u010dar D-K, Tabor AB, Sheppard TD. The application of design of experiments (DoE) reaction optimisation and solvent selection in the development of new synthetic chemistry. Org Biomol Chem. 2016;14(8):2373\u201384.","journal-title":"Org Biomol Chem"},{"key":"2551_CR19","unstructured":"Souza J, Alves J, Damiani J, Silva M, editors. Design of experiments: its importance in the efficient project management. Proceedings of the 22nd International Conference on Production Research, Iguassu Falls, Brazil.\u00a02013;22:1\u20135."},{"issue":"12","key":"2551_CR20","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2174\/1381612826666200218101231","volume":"26","author":"ES L\u00f3pez","year":"2020","unstructured":"L\u00f3pez ES, Machado AL, Vidal LB, Gonz\u00e1lez-Pizarro R, Silva AD, Souto EB. Lipid nanoparticles as carriers for the treatment of neurodegeneration associated with Alzheimer\u2019s disease and glaucoma: present and future challenges. Curr Pharm Des. 2020;26(12):1235\u201350.","journal-title":"Curr Pharm Des"},{"issue":"34","key":"2551_CR21","doi-asserted-by":"publisher","first-page":"21712","DOI":"10.1021\/acsomega.0c02618","volume":"5","author":"N Badawi","year":"2020","unstructured":"Badawi N, El-Say K, Attia D, El-Nabarawi M, Elmazar M, Teaima M. Development of pomegranate extract-loaded solid lipid nanoparticles: quality by design approach to screen the variables affecting the quality attributes and characterization. ACS Omega. 2020;5(34):21712\u201321.","journal-title":"ACS Omega"},{"issue":"4","key":"2551_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/02652048.2022.2079744","volume":"39","author":"B Uner","year":"2022","unstructured":"Uner B, Ozdemir S, Tas C, Ozsoy Y, Uner M. Development of lipid nanoparticles for transdermal loteprednol etabonate delivery. J Microencapsul. 2022;39(4):327\u201340.","journal-title":"J Microencapsul."},{"key":"2551_CR23","unstructured":"Guideline: validation of analytical procedures: textand methodology Q2 (R1). (2005)."},{"key":"2551_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jcis.2017.05.038","volume":"504","author":"T Chantaburanan","year":"2017","unstructured":"Chantaburanan T, Teeranachaideekul V, Chantasart D, Jintapattanakit A, Junyaprasert VB. Effect of binary solid lipid matrix of wax and triglyceride on lipid crystallinity, drug-lipid interaction and drug release of ibuprofen-loaded solid lipid nanoparticles (SLN) for dermal delivery. J Colloid Interface Sci. 2017;504:247\u201356.","journal-title":"J Colloid Interface Sci"},{"issue":"1\u20132","key":"2551_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ijpharm.2003.12.016","volume":"273","author":"F Hu","year":"2004","unstructured":"Hu F, Hong Y, Yuan H. Preparation and characterization of solid lipid nanoparticles containing peptide. Int J Pharm. 2004;273(1\u20132):29\u201335.","journal-title":"Int J Pharm"},{"key":"2551_CR26","first-page":"1","volume":"683153","author":"VD Wagh","year":"2014","unstructured":"Wagh VD, Apar DU. Cyclosporine a loaded PLGA nanoparticles for dry eye disease: in vitro characterization studies. J Nanotechnol. 2014;683153:1\u201310.","journal-title":"J Nanotechnol."},{"issue":"5","key":"2551_CR27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/chromsci\/bmu121","volume":"53","author":"YK Han","year":"2015","unstructured":"Han YK, Segall AI. A validated specific stability-indicating RP-HPLC assay method for the determination of loteprednol etabonate in eye drops. J Chromatogr Sci. 2015;53(5):761\u20136.","journal-title":"J Chromatogr Sci"},{"issue":"3","key":"2551_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193276","volume":"13","author":"L Jin","year":"2018","unstructured":"Jin L, Wu J, Yuan G, Chen T. In vitro study of the inflammatory cells response to biodegradable Mg-based alloy extract. PLoS ONE. 2018;13(3).","journal-title":"PLoS ONE"},{"key":"2551_CR29","unstructured":"Quantikine\u00aeELISA, For the quantitative determination of human interleukin I (IL-I) and interleukin 6 (IL-6) concentrations in cell culture supernates, serum, and plasma. [Internet]. 14 October 2021. Available from: https:\/\/www.bio-techne.com\/datasheet-pdf?src=rnd&pdf=d6050.pdf"},{"key":"2551_CR30","first-page":"117","volume-title":"Characterization and imaging of solid lipid nanoparticles and nanostructured lipid carriers","author":"M \u00dcner","year":"2016","unstructured":"\u00dcner M. Characterization and imaging of solid lipid nanoparticles and nanostructured lipid carriers. Handbook of nanoparticles: Springer; 2016. p. 117\u201341."},{"issue":"4","key":"2551_CR31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2174\/2211738503666150327002434","volume":"2","author":"A Hirani","year":"2014","unstructured":"Hirani A, Lee W, Y, Pathak Y, Sutariya V. Efficacy of loteprednol etabonate drug delivery system in suppression of in vitro retinal pigment epithelium activation. Pharmaceutical Nanotechnology. 2014;2(4):208\u201316.","journal-title":"Pharmaceutical Nanotechnology."},{"issue":"2","key":"2551_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0378-5173(98)00092-1","volume":"168","author":"C Freitas","year":"1998","unstructured":"Freitas C, M\u00fcller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN\u2122) dispersions. Int J Pharm. 1998;168(2):221\u20139.","journal-title":"Int J Pharm"},{"issue":"1","key":"2551_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0378-5173(03)00229-1","volume":"260","author":"J Hamdani","year":"2003","unstructured":"Hamdani J, Mo\u00ebs AJ, Amighi K. Physical and thermal characterisation of Precirol\u00ae and Compritol\u00ae as lipophilic glycerides used for the preparation of controlled-release matrix pellets. Int J Pharm. 2003;260(1):47\u201357.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"2551_CR34","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.10.003","volume":"366","author":"J Pardeike","year":"2009","unstructured":"Pardeike J, Hommoss A, M\u00fcller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1\u20132):170\u201384.","journal-title":"Int J Pharm"},{"issue":"1","key":"2551_CR35","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.colsurfb.2011.07.036","volume":"88","author":"S Das","year":"2011","unstructured":"Das S, Ng WK, Kanaujia P, Kim S, Tan RB. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf, B. 2011;88(1):483\u20139.","journal-title":"Colloids Surf, B"},{"key":"2551_CR36","unstructured":"Toameh D. Development of in vitro biocompatibility models of the ocular surface: University of Waterloo; 2020."},{"issue":"1","key":"2551_CR37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijpharm.2004.02.032","volume":"278","author":"E Souto","year":"2004","unstructured":"Souto E, Wissing S, Barbosa C, M\u00fcller R. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 2004;278(1):71\u20137.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"2551_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0378-5173(02)00080-7","volume":"238","author":"R Cavalli","year":"2002","unstructured":"Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm. 2002;238(1\u20132):241\u20135.","journal-title":"Int J Pharm"},{"key":"2551_CR39","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.exer.2016.08.010","volume":"151","author":"Q Qin","year":"2016","unstructured":"Qin Q, Luo D, Shi Y, Zhao Q, Chen Y, Wu J, et al. CD25 siRNA induces Treg\/Th1 cytokine expression in rat corneal transplantation models. Exp Eye Res. 2016;151:134\u201341.","journal-title":"Exp Eye Res"},{"key":"2551_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2021.108539","volume":"206","author":"I-L Tsai","year":"2021","unstructured":"Tsai I-L, Tsai C-Y, Kuo L-L, Woung L-C, Ku R-Y, Cheng Y-H. PLGA nanoparticles containing Lingzhi extracts rescue corneal epithelial cells from oxidative damage. Exp Eye Res. 2021;206.","journal-title":"Exp Eye Res"},{"issue":"7","key":"2551_CR41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3109\/10717544.2010.483257","volume":"17","author":"A Seyfoddin","year":"2010","unstructured":"Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug delivery. Drug Delivery. 2010;17(7):467\u201389.","journal-title":"Drug Delivery"},{"issue":"1","key":"2551_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3109\/02652040902846883","volume":"27","author":"E Ba\u015faran","year":"2010","unstructured":"Ba\u015faran E, Demirel M, S\u0131rmag\u00fcl B, Yazan Y. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul. 2010;27(1):37\u201347.","journal-title":"J Microencapsul"},{"issue":"4","key":"2551_CR43","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3109\/03639045.2012.665460","volume":"39","author":"A Seyfoddin","year":"2013","unstructured":"Seyfoddin A, Al-Kassas R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm. 2013;39(4):508\u201319.","journal-title":"Drug Dev Ind Pharm"},{"issue":"3","key":"2551_CR44","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/03639045.2020.1724135","volume":"46","author":"VR Rathod","year":"2020","unstructured":"Rathod VR, Shah DA, Dave RH. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables. Drug Dev Ind Pharm. 2020;46(3):443\u201355.","journal-title":"Drug Dev Ind Pharm"},{"key":"2551_CR45","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejpb.2022.02.010","volume":"172","author":"R Varela-Fern\u00e1ndez","year":"2022","unstructured":"Varela-Fern\u00e1ndez R, Garc\u00eda-Otero X, D\u00edaz-Tom\u00e9 V, Regueiro U, L\u00f3pez-L\u00f3pez M, Gonz\u00e1lez-Barcia M, et al. Lactoferrin-loaded nanostructured lipid carriers (NLCs) as a new formulation for optimized ocular drug delivery. Eur J Pharm Biopharm. 2022;172:144\u201356.","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"2551_CR46","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00063030-199810040-00007","volume":"10","author":"S Noble","year":"1998","unstructured":"Noble S, Goa KL. Loteprednol etabonate. BioDrugs. 1998;10(4):329\u201339.","journal-title":"BioDrugs"},{"key":"2551_CR47","unstructured":"Albinus M, Amschler G, Amschler U, von Angerer E, Barthel W, Bauer A, et al. T. In: Albinus M, Amschler G, Amschler U, von Angerer E, Barthel W, Bauer A, et al., editors. Hagers Handbuch der Pharmazeutischen Praxis. Berlin, Heidelberg: Springer Berlin Heidelberg; 1994. p. 765-1129."},{"issue":"1\u20132","key":"2551_CR48","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.ijpharm.2014.08.001","volume":"473","author":"B Clares","year":"2014","unstructured":"Clares B, Calpena AC, Parra A, Abrego G, Alvarado H, Fangueiro JF, et al. Nanoemulsions (NEs), liposomes (LPs) and solid lipid nanoparticles (SLNs) for retinyl palmitate: effect on skin permeation. Int J Pharm. 2014;473(1\u20132):591\u20138.","journal-title":"Int J Pharm"},{"issue":"4","key":"2551_CR49","doi-asserted-by":"publisher","DOI":"10.1063\/1.5040316","volume":"12","author":"E Guzniczak","year":"2018","unstructured":"Guzniczak E, Jimenez M, Irwin M, Otto O, Willoughby N, Bridle H. Impact of poloxamer 188 (Pluronic F-68) additive on cell mechanical properties, quantification by real-time deformability cytometry. Biomicrofluidics. 2018;12(4).","journal-title":"Biomicrofluidics"},{"issue":"4","key":"2551_CR50","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.vetmic.2007.04.010","volume":"123","author":"M Beekes","year":"2007","unstructured":"Beekes M, Lasch P, Naumann D. Analytical applications of Fourier transform-infrared (FT-IR) spectroscopy in microbiology and prion research. Vet Microbiol. 2007;123(4):305\u201319.","journal-title":"Vet Microbiol"},{"issue":"7","key":"2551_CR51","first-page":"392","volume":"61","author":"J Mansbridge","year":"2020","unstructured":"Mansbridge J, Morhenn V. Tape stripping: a novel noninvasive method using RNA sequences for diagnosing ocular surface diseases of the eye and eyelid. Investigative Ophthalmology & Visual Science. 2020;61(7):392.","journal-title":"Investigative Ophthalmology & Visual Science."},{"key":"2551_CR52","first-page":"5811","volume":"12","author":"S Shiyan","year":"2022","unstructured":"Shiyan S, Suryani RP, Mulyani LN, Pratiwi G. Stability study of super saturable catechin-self nano emulsifying drug delivery system as antidiabetic therapy. Biointerface Res Appl Chem. 2022;12:5811\u201320.","journal-title":"Biointerface Res Appl Chem"},{"issue":"4","key":"2551_CR53","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s12325-016-0315-8","volume":"33","author":"JD Sheppard","year":"2016","unstructured":"Sheppard JD, Comstock TL, Cavet ME. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv Ther. 2016;33(4):532\u201352.","journal-title":"Adv Ther"},{"issue":"10","key":"2551_CR54","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1023\/A:1015849132396","volume":"9","author":"N Bodor","year":"1992","unstructured":"Bodor N, Loftsson T, Wu W-M. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Pharm Res. 1992;9(10):1275\u20138.","journal-title":"Pharm Res"},{"key":"2551_CR55","first-page":"1","volume":"81","author":"B Uner","year":"2023","unstructured":"Uner B, Ozdemir S, Yildirim E, Yaba A, Ozsoy Y, Uner M. Loteprednol loaded nanoformulations for corneal delivery: Ex-vivo permeation study, ocular safety assessment and stability studies. J Drug Deliv Sci Technol. 2023;81:1\u201310.","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"2","key":"2551_CR56","doi-asserted-by":"publisher","first-page":"327","DOI":"10.23812\/CONTI-E","volume":"34","author":"P Conti","year":"2020","unstructured":"Conti P, Ronconi G, Caraffa A, Gallenga C, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327\u201331.","journal-title":"J Biol Regul Homeost Agents"},{"issue":"3","key":"2551_CR57","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","volume":"33","author":"T Hirano","year":"2021","unstructured":"Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127\u201348.","journal-title":"Int Immunol"},{"key":"2551_CR58","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/OPTH.S323301","volume":"16","author":"N Venkateswaran","year":"2022","unstructured":"Venkateswaran N, Bian Y, Gupta PK. Practical guidance for the use of loteprednol etabonate ophthalmic suspension 0.25% in the management of dry eye disease. Clin Ophthalmol. 2022;16:349\u201355.","journal-title":"Clin Ophthalmol."}],"updated-by":[{"DOI":"10.1208\/s12249-025-03278-2","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"record-id":"69333"},{"DOI":"10.1208\/s12249-025-03278-2","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000}}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-023-02551-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-023-02551-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-023-02551-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:03:17Z","timestamp":1762344197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-023-02551-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":58,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["2551"],"URL":"https:\/\/doi.org\/10.1208\/s12249-023-02551-6","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"assertion":[{"value":"12 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1208\/s12249-025-03278-2","URL":"https:\/\/doi.org\/10.1208\/s12249-025-03278-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"92"}}